BioXcel Therapeutics amended its credit agreement with Oaktree Fund Administration to gain temporary financial relief. The agreement lowers the company's minimum cash liquidity requirement from $6.25 million to $3.0 million. This modification represents the twelfth amendment to the credit facility.
The amendment extends a critical deadline to August 21, 2026. BioXcel must finalize a debt repayment plan or secure an alternative capital solution by this date. The company continues to navigate significant operating losses while seeking a sustainable financial path.